Stuart A. Arbuckle - 22 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
22 Feb 2023
Net transactions value
-$706,679
Form type
4
Filing time
24 Feb 2023, 15:06:38 UTC
Previous filing
22 Feb 2023
Next filing
28 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $37,647 -129 -0.19% $291.84 68,576 22 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $87,858 -300 -0.44% $292.86 68,276 22 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $405,532 -1,378 -2% $294.29 66,898 22 Feb 2023 Direct F1, F2, F5
transaction VRTX Common Stock Sale $116,380 -394 -0.59% $295.38 66,504 22 Feb 2023 Direct F1, F2, F6
transaction VRTX Common Stock Sale $59,262 -200 -0.3% $296.31 66,304 22 Feb 2023 Direct F1, F2, F7
holding VRTX Common Stock 140 22 Feb 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $291.84 (range $291.17 to $292.03).
F4 Open market sales reported on this line occurred at a weighted average price of $292.86 (range $292.44 to $293.37).
F5 Open market sales reported on this line occurred at a weighted average price of $294.29 (range $293.83 to $294.82).
F6 Open market sales reported on this line occurred at a weighted average price of $295.38 (range $294.83 to $295.72).
F7 Open market sales reported on this line occurred at a weighted average price of $296.31 (range $296.20 to $296.41).